Efficacy and safety of PD-1/PD-L1 inhibitors plus nab-paclitaxel for patients with non-small cell lung cancer who have progressed after platinum-based chemotherapy

Efficacy and safety of PD-1/PD-L1 inhibitors plus nab-paclitaxel for patients with non-small cell lung cancer who have progressed after platinum-based chemotherapy

Background: Immunotherapy combined with platinum-based chemotherapy is now the standard first-line treatment for non-small cell lung cancer (NSCLC) patients. However, limited evidence exists to show the efficacy of immunotherapy plus taxanes for patients who have progressed after platinum-based chem...

Full description

Bibliographic Details
Main Authors: Fan Zhang, Di Huang, Lei Zhao, Tao Li, Sujie Zhang, Guoqing Zhang, Fang Yuan, Jie Zhang, Yuzi Zhang, Zhengyi Zhao, Longgang Cui, Jing Zhao, Guoqiang Wang, Shangli Cai, Yuezong Bai, Jinliang Wang, Yi Hu
Format: Article
Language:English
Published: SAGE Publishing 2020-07-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/1758835920936882

Internet

https://doi.org/10.1177/1758835920936882

Similar Items